Literature DB >> 30580891

Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction.

Akinori Sugano1, Yoshihiro Seo2, Tomoko Ishizu1, Seika Sai1, Masayoshi Yamamoto1, Yoshie Hamada-Harimura1, Tomoko Machino-Ohtsuka1, Kenichi Obara3, Isao Nishi4, Kazutaka Aonuma1, Akihiko Nogami1.   

Abstract

BACKGROUND: Soluble ST2 (sST2) is a marker of inflammation and fibrosis, which is a significant predictor of prognosis of heart failure (HF), independent of brain natriuretic peptide (BNP). This study aimed to clarify how sST2 associates with clinical outcome through investigations of clinical correlates and mode of death in patients with heart failure with preserved ejection fraction (HFpEF).
METHODS: A total 191 patients with acute decompensated HF and EF ≥50% were prospectively enrolled. Echocardiographic and laboratory data including sST2 were obtained in pre-discharge stable condition.
RESULTS: Serum sST2 level showed significant positive correlations with C-reactive protein and pentraxin3 levels, and negative correlations with body mass index, albumin, and hemoglobin. Serum sST2 level was significantly higher in patients with all-cause death and non-cardiovascular (CV) death compared to those without events, whereas there was no significant difference in sST2 level between patients with and without CV death. On the other hand, BNP level was significantly higher in patients with all-cause death and CV death compared to those without events. Cox regression analyses adjusted for age and sex revealed that sST2 was a significant predictor of non-CV death, whereas BNP was a significant predictor of CV death.
CONCLUSIONS: Serum sST2 level was associated with non-CV death showing significant correlations with systemic factors including malnutrition and inflammation, while BNP was associated with CV death.
Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain natriuretic peptide; Heart failure with preserved ejection fraction; Soluble ST2; Systemic inflammation

Mesh:

Substances:

Year:  2018        PMID: 30580891     DOI: 10.1016/j.jjcc.2018.10.012

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  7 in total

Review 1.  Soluble ST2: a valuable prognostic marker in heart failure.

Authors:  Sugeevan Savarimuthu; Pavan Goel; Amer Harky
Journal:  Heart Fail Rev       Date:  2022-06-27       Impact factor: 4.654

2.  Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction.

Authors:  Lindsey Aurora; Edward Peterson; Hongsheng Gui; Nicole Zeld; James McCord; Yigal Pinto; Bernard Cook; Hani N Sabbah; L Keoki Williams; James Snider; David E Lanfear
Journal:  Clin Chim Acta       Date:  2020-09-12       Impact factor: 3.786

3.  Circulating Soluble ST2 Predicts All-Cause Mortality in Severe Heart Failure Patients with an Implantable Cardioverter Defibrillator.

Authors:  Zhi-Wei Hou; Hai-Bo Yu; Yan-Chun Liang; Yang Gao; Guo-Qing Xu; Min Wu; Zhu Mei; Zu-Lu Wang; Zhi-Guo Li; Yu-Ying Li; Hai-Xu Song; Jia-Yin Li; Ya-Ling Han
Journal:  Cardiol Res Pract       Date:  2020-11-17       Impact factor: 1.866

Review 4.  Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond.

Authors:  Paolo Morfino; Alberto Aimo; Vincenzo Castiglione; Giuseppe Vergaro; Michele Emdin; Aldo Clerico
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-10

5.  Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Authors:  Yujiao Shi; Jiangang Liu; Chunqiu Liu; Xiong Shuang; Chenguang Yang; Wenbo Qiao; Guoju Dong
Journal:  Front Cardiovasc Med       Date:  2022-09-20

6.  Correlation of serum ST2 levels with severity of diastolic dysfunction on echocardiography and findings on cardiac MRI in patients with heart failure with preserved ejection fraction.

Authors:  Vivek Agrawal; Suhas Hardas; Hasmukh Gujar; Deepak S Phalgune
Journal:  Indian Heart J       Date:  2022-03-09

Review 7.  Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Authors:  Ishan Lakhani; Michelle Vangi Wong; Joshua Kai Fung Hung; Mengqi Gong; Khalid Bin Waleed; Yunlong Xia; Sharen Lee; Leonardo Roever; Tong Liu; Gary Tse; Keith Sai Kit Leung; Ka Hou Christien Li
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.